In Reply

Obstet Gynecol. 2015 Oct;126(4):900-901. doi: 10.1097/AOG.0000000000001075.

Authors

Eman Elgindy¹, Magdy Mostafa, Hoda Sibai, Amany Abdelghani

Affiliation

¹ Department of Obstetrics and Gynecology, Zagazig University School of Medicine, Zagazig, Egypt Department of Obstetrics and Gynecology, Cairo University Faculty of Medicine, El Manial, Cairo, Egypt Department of Obstetrics and Gynecology, Zagazig University School of Medicine, Zagazig, Egypt.

PMID: 26393448
DOI: 10.1097/AOG.0000000000001075

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents / adverse effects*
Female
Fertility Preservation / methods*
Gonadotropin-Releasing Hormone / therapeutic use*
Humans
Pregnancy
Primary Ovarian Insufficiency / prevention & control*
Protective Agents / therapeutic use*

Substances

Antineoplastic Agents
Protective Agents
Gonadotropin-Releasing Hormone